The race for a coronavirus vaccine shows no signs of slowing as more companies move their vaccine candidates through clinical trials, growing closer to determining which will be considered safe and effective.
One such candidate is in development by the American pharmaceutical company Pfizer, which announced along with its German partner BioNTech on Saturday they proposed expanding Phase 3 clinical trials to include 44,000 participants and more diverse patient populations, including people as young as 16.
That's up from the initial plan of 30,000 participants, a benchmark they plan to meet next week, according to a news release.
Diversity matters: The proposal, which would need approval by the Food and Drug Administration, would allow the companies to collect more data on the safety and efficacy of the vaccine candidate while diversifying the pool of participants.
"I think we should strive to have as more diverse population as possible," Pfizer CEO Albert Bourla told CBS on "Face the Nation" Sunday, stressing the importance of having a diverse group of volunteers given the heightened impact Covid-19 has had on communities of color.
"But right now we are not bad. Actually, we have a population that globally only 60% are Caucasians, 40%, approximately, minorities," he said.
Read the full story: